Study wrapper · #1037
Cardiovascular Outcomes of GLP-1-Based Medicines Among People With Overweight and Obesity: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials.
Editor's note
An umbrella review synthesizing nine meta-analyses of GLP-1-based medicines and cardiovascular outcomes in overweight and obese populations, graded with GRADE. High-certainty evidence supported reduced MACE and myocardial infarction, but the benefit was driven by patients with established cardiovascular disease and lost significance in primary-prevention groups. Tirzepatide is the specifically tracked agent here, with signals of both cardiac benefit and increased heart rate that merit attention.
Plain-language abstract
This umbrella review of meta-analyses found that GLP-1 receptor agonists are associated with reduced major cardiac events and heart attacks in people with overweight or obesity, though the benefit was concentrated in those with existing cardiovascular disease. Tirzepatide showed benefit for major cardiac events but was also associated with increased heart rate.